Endotyping, phenotyping and personalised therapy in obstructive sleep apnoea: are we there yet?
- PMID: 37217289
- DOI: 10.1136/thorax-2023-220037
Endotyping, phenotyping and personalised therapy in obstructive sleep apnoea: are we there yet?
Abstract
Obstructive sleep apnoea (OSA) was traditionally thought to be mainly caused by obesity and upper airway crowding, and hence OSA management was not personalised according to particular characteristics, with most symptomatic patients receiving continuous positive airway pressure therapy. Recent advances in our understanding have identified additional potential and distinct causes of OSA (endotypes), and subgroups of patients (phenotypes) with increased risk of cardiovascular complications. In this review, we discuss the evidence to date as to whether there are distinct clinically useful endotypes and phenotypes of OSA, and the challenges to the field in moving towards delivering personalised therapy in OSA.
Keywords: Sleep apnoea.
© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: CDT reports honoraria from Stowood Scientific, outside the scope of this submission. There are no other relevant competing interests.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources